Ruiz et al. bDMARD/tsDMARD use in RA after breast cancer. Low use, 15.5% on bDMARD, 1.5% on tsDMARD. Stable use over last 10 years @rheumnow #ACR22 Abstr#0080 https://t.co/0L6uuVtQQw https://t.co/xBH1bUdeSD
Links:
Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in…
https://acrabstracts.org/abstract/utilization-of-biologic-and-targeted-disease-…
12-11-2022
